First Wave BioPharma Analysis
| FWBIDelisted Stock | USD 0.61 0.03 4.69% |
First Wave BioPharma is overvalued with Real Value of 0.58 and Hype Value of 0.61. The main objective of First Wave delisted stock analysis is to determine its intrinsic value, which is an estimate of what First Wave BioPharma is worth, separate from its market price. There are two main types of First Wave's stock analysis: fundamental analysis and technical analysis.
The First Wave stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and First Wave's ongoing operational relationships across important fundamental and technical indicators.
First |
First Stock Analysis Notes
The company has price-to-book (P/B) ratio of 1.87. Some equities with similar Price to Book (P/B) outperform the market in the long run. First Wave BioPharma recorded a loss per share of 47.88. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 18th of December 2023. First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida. First Wave operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. To learn more about First Wave BioPharma call RPh MBA at 561 589 7020 or check out https://www.firstwavebio.com.First Wave BioPharma Investment Alerts
| First Wave BioPharma is now traded under the symbol ENTO. Please update your portfolios or report it if you believe this is an error. Report It! | |
| First Wave BioPharma is not yet fully synchronised with the market data | |
| First Wave BioPharma has some characteristics of a very speculative penny stock | |
| First Wave BioPharma has a very high chance of going through financial distress in the upcoming years | |
| First Wave BioPharma currently holds 826.84 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. First Wave BioPharma has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about First Wave's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| First Wave BioPharma currently holds about 1.16 M in cash with (12.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
First Wave BioPharma Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to First Wave previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
First Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.99 M.First Wave BioPharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific First Wave insiders, such as employees or executives, is commonly permitted as long as it does not rely on First Wave's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases First Wave insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Romano Sarah over six months ago Acquisition by Romano Sarah of 150000 shares of First Wave subject to Rule 16b-3 | ||
Romano Sarah over six months ago Disposition of tradable shares by Romano Sarah of First Wave at 4.2294 subject to Rule 16b-3 | ||
Romano Sarah over six months ago Disposition of 1120 shares by Romano Sarah of First Wave at 4.96 subject to Rule 16b-3 | ||
Schneiderman Daniel H over six months ago Disposition of tradable shares by Schneiderman Daniel H of First Wave subject to Rule 16b-3 | ||
Sapirstein James over a year ago Acquisition or disposition of First Wave securities by Sapirstein James | ||
Romano Sarah over a year ago Sale by Romano Sarah of 1676 shares of First Wave | ||
Romano Sarah over a year ago Sale by Romano Sarah of 1977 shares of First Wave |
First Wave Outstanding Bonds
First Wave issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. First Wave BioPharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most First bonds can be classified according to their maturity, which is the date when First Wave BioPharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
First Wave Predictive Daily Indicators
First Wave intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of First Wave stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About First Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how First Wave prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling First shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as First Wave. By using and applying First Stock analysis, traders can create a robust methodology for identifying First entry and exit points for their positions.
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida. First Wave operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding First Wave to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in First Stock
If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |